Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Multi-Drug Resistant Tuberculosis

This video summarizes the key elements of the multi-faceted, private-public partnership that has been assembled by Lilly to meet the challenge of MDR-TB. Several world-recognized experts from academia, international agencies, and from within the company talk about the challenges that developing nations face in implementing sound containment programs given the lack of awareness, adequately trained personnel and access to affordable drugs.

Author:

Eli Lilly and Company, Eli Lilly and Company

Audiences:

Managers and Supervisors

Topic:

MDR TB, TB Treatment, Treatment- Medication Information, Partnership Building

Country of Origin:

United States

View Webpage

Related Materials

TB Guidelines for Nurses in the Care and Control of Tuberculosis and Multi-Drug Resistant Tuberculosis

This guideline is intended to help nurses in their role of detecting TB cases, providing care, and managing TB treatment. It provides a nursing approach to planning and delivering patient care, aimed at improving access and quality of care throughout the treatment period. It offers a review of TB and multidrug-resistant TB (MDR TB) and the directly observed treatment short-course (DOTS) and DOTS-Plus strategy, as well as guidance on how to adapt TB control information for local program implementation. Also included is an overview of organizational issues that can have an important impact on TB control programs.

Guideline

The Use of Bedaquiline in the Treatment of Multi-Drug Resistant Tuberculosis: Interim Policy Guidance

This interim guidance provides advice on the inclusion of bedaquiline in the combination therapy of MDR-TB in accordance with the existing WHO Guidelines for the Programmatic Management of Drug-resistant TB (2011 Update).

Guideline

Generic Programmatic and Clinical Guide for the Introduction of New Drugs and Shorter Regimen for Treatment of Multi/Extensively Drug-Resistant Tuberculosis

This document describes the steps necessary to implement the shorter regimen and the new drugs for drug-resistant TB treatment, including diagnosis and bacterial confirmation of drug resistance, treatment regimen design, monitoring of treatment efficacy and safety, and programmatic evaluation.

Guideline

Global resources for the prevention,
management, and elimination of TB.